Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Inventory: 2010-2025

Historic Inventory for China Pharma Holdings (CPHI) over the last 15 years, with Sep 2025 value amounting to $2.7 million.

  • China Pharma Holdings' Inventory rose 9.71% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 9.71%. This contributed to the annual value of $2.8 million for FY2024, which is 26.46% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Inventory is $2.7 million, which was up 2.31% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Inventory registered a high of $3.9 million during Q2 2023, and its lowest value of $2.5 million during Q3 2024.
  • In the last 3 years, China Pharma Holdings' Inventory had a median value of $2.8 million in 2024 and averaged $3.2 million.
  • In the last 5 years, China Pharma Holdings' Inventory spiked by 31.01% in 2023 and then crashed by 33.66% in 2024.
  • Over the past 5 years, China Pharma Holdings' Inventory (Quarterly) stood at $2.9 million in 2021, then remained steady at $2.9 million in 2022, then surged by 31.01% to $3.9 million in 2023, then decreased by 26.46% to $2.8 million in 2024, then grew by 9.71% to $2.7 million in 2025.
  • Its Inventory stands at $2.7 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.